ALIMERA SCIENCES, INC. (NASDAQ:ALIM) Files An 8-K Submission of Matters to a Vote of Security Holders

0

ALIMERA SCIENCES, INC. (NASDAQ:ALIM) Files An 8-K Submission of Matters to a Vote of Security Holders

Item 5.07. Submission of Matters to a Vote of Security Holders.

At the 2017 annual meeting of stockholders of Alimera Sciences,
Inc. (the Company) held on June 22, 2017 (the Annual Meeting),
the following proposals were submitted to the stockholders of the
Company:
Proposal 1:
The election of three directors to serve as Class I
directors for a term of three years until the 2020
annual meeting of stockholders.
Proposal 2:
The ratification of the selection of Grant Thornton LLP
as the Companys independent registered public
accounting firm for the fiscal year ending December 31,
2017.
Proposal 3:
The approval on an advisory, non-binding basis of the
compensation of the Companys named executive officers.
Proposal 4:
The advisory, non-binding vote on the frequency of
stockholder advisory, non-binding votes on the
compensation of our named executive officers.
For more information about the foregoing proposals, see the
Companys definitive proxy statement on Schedule 14A (Amendment
No. 1) filed with the Securities and Exchange Commission on May
3, 2017 (the Proxy Statement). Of the 64,862,904 shares of the
Companys common stock, including 8,135,593 shares of common stock
underlying the Companys outstanding Series A Preferred Stock
(based on a deemed conversion price of $2.95 per share), entitled
to vote at the Annual Meeting, 51,167,771 shares, or
approximately 78.89%, were represented at the meeting in person
or by proxy, constituting a quorum. The number of votes cast for,
against or withheld, as well as abstentions and broker non-votes,
if applicable, in respect of each such matter is set forth below:
Proposal 1:
Election of Directors.
The Companys stockholders elected the following three directors
to serve as Class I directors until the 2020 annual meeting of
stockholders. The votes regarding the election of directors were
as follows:
Director
Votes For
Votes Withheld
Broker Non-Votes
James R. Largent
33,603,751
487,037
17,076,983
C. Daniel Myers
33,296,651
794,137
17,076,983
Calvin W. Roberts, M.D.
33,605,751
485,037
17,076,983
Proposal 2:
Ratification of Selection of Grant Thornton LLP.
The Companys stockholders ratified the selection of Grant
Thornton LLP as the Companys independent registered public
accounting firm for the fiscal year ending December 31, 2017. The
votes regarding this proposal were as follows:
Votes For
Votes Against
Votes Abstaining
Broker Non-Votes
50,221,866
738,940
206,965
Proposal 3:
Compensation of Named Executive Officers.
The Companys stockholders approved on an advisory, non-binding
basis the compensation paid to the Companys named executive
officers, as disclosed in the Proxy Statement. The votes
regarding this proposal were as follows:
Votes For
Votes Against
Votes Abstaining
Broker Non-Votes
32,590,385
1,277,338
223,065
17,076,983
Proposal 4:
The Frequency of a Vote on Executive Compensation.
The Companys stockholders approved on advisory, non-binding basis
the option of every 1 year for the frequency of holding an
advisory, non-binding vote on executive compensation. The votes
regarding this proposal were as follows:
Votes for 1 Year
Votes for 2 Years
Votes for 3 Years
Votes Abstaining
Broker Non-Votes
33,038,435
414,327
412,044
225,982
17,076,983
In accordance with the recommendation of the Companys Board of
Directors as set forth in the Proxy Statement, and based on the
voting results for this Proposal 4, the Companys Board of
Directors determined that an advisory vote to approve the
compensation of the Companys named executive officers will be
conducted on an annual basis. The Companys Board of Directors
will reevaluate this determination after the next stockholder
advisory vote on this matter is held.


About ALIMERA SCIENCES, INC. (NASDAQ:ALIM)

Alimera Sciences, Inc. (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina. The Company’s product is ILUVIEN, which is developed to treat diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness. In the United States, ILUVIEN is indicated for the treatment of DME in patients who have been treated with a course of corticosteroids and did not have a rise in intraocular pressure (IOP). In the European Economic Area (EEA) countries, ILUVIEN is indicated for the treatment of vision impairment associated with DME considered insufficiently responsive to available therapies.